September 18, 2017 – Claret Medical announced publication of a new study in the Journal of the American College of Cardiology (JACC): Cardiovascular Interventions that underscores the role of the Sentinel Cerebral Protection System (CPS) in significantly reducing the early occurrence of stroke associated with

Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its QMAPP hemodynamic monitoring system.

Hitachi Healthcare Americas Inc. announced it has attained U.S. Food and Drug Administration (FDA) 510(k) clearance to market its Supria True64 computed tomography (CT) system.

September 15, 2017 — Philips highlighted its newest solution for nuclear cardiology, CardioMD IV, at the American Society of Nuclear Cardiology’s Annual Scientific Session, Sept. 14-17 in Kansas City, Mo.

September 14, 2017 — Scientists at the National Institutes of Health have expanded the understanding of how chronic inflammation and persistent immune activation associated with HIV infection drive cardiovascular disease risk in people living with HIV. People living with HIV are up to twice as likely to experience heart attacks, strokes and other forms of cardiovascular disease as people who do not have the virus, even when HIV infection is well-controlled with the use of antiretroviral therapy.

Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently in the European Journal of Preventive Cardiology.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials presented at VIVA 2017 this week. The large vascular conference is sponsored by VIVA Physicians, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research. 

 

First Prospective Multicenter Study Evaluating Outcomes Following EVAR in Women vs Men: Early Results From the LUCY Study
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now